VANCOUVER, BC, March 2, 2021 /CNW/ – Ron Scorsese, TechBomb Contributor.
Today Mind Cure Health Incorporated who use use psilocybin, the active ingredient in psychedelics, to treat patients confirmed they have dropped half a million dollars of investment into ATMA Journey Centers Inc. ATMA, an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, sees today’s announcement as “a huge step forward for healing today in Canada and around the world”.
Last December, Mind Cure Health Incorporated, announced its plans to open the first Mind Cure Health Center, which will offer psychedelic-assisted mental health therapy to patients as well as training to therapists. Located in Kelowna, British Columbia, the center is scheduled to open in May of 2021, and will offer patients access to therapeutic treatments with ketamine and psilocybin through utilizing Section 56 Exemptions, a legal exemption to Canadian drug laws granted by Health Canada.
Since then, Health Canada has approved 24 more applications from cancer patients for treatment of end-of-life distress. It has also granted exemptions to 19 health-care providers, giving them the right to possess and use mushrooms containing psilocybin for professional training purposes, a spokeswoman said in a statement.
Related Stories
- In a landmark decision, four Canadians suffering from terminal illnesses have been approved to receive psilocybin therapy to treat their anxiety — marking the first time that a legal exemption has been given in Canada for patients to access psychedelic substances for treatment. CTV reported Four terminally ill Canadians get special exemption to use psychedelic therapy
The department has yet to decide whether it will allow the public to use any psychedelics for therapeutic purposes beyond the exemptions it has granted so far but it looks like they have with ATMA investor Mind Cure.
ATMA, who in February launched a program to help medical professionals treat patients using the fun mushroom has been busy growing. If you are treating patients it’s probably a good idea to try the product according to ATMA. Each participant of the professional training program will also be assisted in obtaining their own exemption from Health Canada so that they may personally undergo psychedelic-assisted therapy. This unique element of the training will provide each professional the personal perspective to truly understand and experience how psychedelics can benefit their patients.
ATMA said “We are a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world.”
ATMA was the first private sector service provider in Canada to announce conducting legal psychedelic-assisted therapy for a palliative care patient under the approval of Health Canada’s section 56(1) exemption.
“While Health Canada continues to increase access to legal psychedelic-assisted therapy for patients through their recent Section 56 Exemptions, there is a growing need in the mental health industry for therapists to have the appropriate training and knowledge to facilitate this important work.”
Feb 12, 2021 – David Harder, Co-CEO of ATMA
As for Mind Cure the company claims it exists as a response to the current mental health crisis and urgent calls for effective treatments. Mind Cure believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
Mind Cure is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. Mind Cure is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
“Our partnership with ATMA represents a huge step forward for healing today in Canada and around the world. By accelerating the development of our research and technology platform, iSTRYM, we’re closer to minimizing the gaps that exist in health care, all the way from research to the deployment of care. It’s an amazing opportunity to innovate with pioneers of the psychedelic therapy industry by creating proprietary research, identifying commonalities, and driving real transformative results for individuals using psychedelic medicines”
Kelsey Ramsden, President & CEO, MINDCURE.
As for medical use of magic mushrooms this author has tried them, in a leisurely manner, multiple times back in high school. I can attest with no medical expertise that further studies should be granted to explore their marvels man.
